What is RNAZ's current stock price?

RNAZ (TransCode Therapeutics, Inc.) is currently trading at $6.24 with a market cap of $5.9M.

What sector is TransCode Therapeutics, Inc. in?

TransCode Therapeutics, Inc. (RNAZ) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

RNAZ TransCode Therapeutics, Inc.

Healthcare

$6.24+2.04%ClosedMarket Cap: $5.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

0.04

P/S

0.00

EV/EBITDA

0.23

DCF Value

$30.08

FCF Yield

-84225.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-99.4%

ROA

-25.7%

ROIC

-21.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-17.8M	$—
Q4 null	$0.00	$-13.4M	$—
FY null	$0.00	$-34.7M	$—
Q3 null	$0.00	$-4.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

STOVER JACK Edirector:

SellMon Dec 22

CZEREPAK ELIZABETHdirector:

SellMon Dec 22

Marquet Magdadirector

SellTue Jun 18

Manting Erikdirector

SellTue Jun 18

Fitzgerald Thomas Adirector, officer: Interim CEO, CFO

SellTue Jun 18

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.40

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Peers